Talking Tumors: Adaptive Approaches in Triple-Negative and HR-Positive Breast Cancers

Jane L. Meisel, MD, and Aditya Bardia, MD, MPH, shed light on treatment considerations for women with triple-negative breast cancer (TNBC) who are candidates for neoadjuvant therapy, emerging treatment strategies for patients with metastatic TNBC, as well as the optimal timing of genomic testing in women with progressive hormone receptor–positive disease.